A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.

Kayki-Mutlu, Gizem; Aksoyalp, Zinnet Sevval; Wojnowski, Leszek; Michel, Martin C

Kayki-Mutlu, Gizem; Aksoyalp, Zinnet Sevval; Wojnowski, Leszek; Michel, Martin C.

Afiliação

Kayki-Mutlu G; Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
Aksoyalp ZS; Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey.
Wojnowski L; Department of Pharmacology, University Medical Center, Universitätsmedizin Mainz, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany.
Michel MC; Department of Pharmacology, University Medical Center, Universitätsmedizin Mainz, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany. marmiche@uni-mainz.de.

Naunyn Schmiedebergs Arch Pharmacol ; 396(8): 1619-1632, 2023 08.

Article em En | MEDLINE | ID: mdl-36951997

Assuntos

Produtos Biológicos; COVID-19; Estados Unidos; Humanos; United States Food and Drug Administration; Pandemias; Preparações Farmacêuticas; Aprovação de Drogas

Palavras-chave

FDA; First-in-class; New drugs; Next-in-class

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / COVID-19 Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google